| P2093 | author name string | Andrea Wang-Gillam | |
| | Lingling Du | |
| | Zheng Che | |
| P2860 | cites work | MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 |
| | Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial | Q39537308 |
| | Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo | Q39964720 |
| | Hyaluronan stimulates pancreatic cancer cell motility | Q39997796 |
| | Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. | Q40860251 |
| | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Q40875359 |
| | Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. | Q41670809 |
| | Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma | Q42811795 |
| | Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development | Q45401730 |
| | Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. | Q53050181 |
| | CD40 expression and its prognostic significance in human gastric carcinoma. | Q53621861 |
| | CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy | Q58235013 |
| | CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help | Q77402954 |
| | Cellular signaling by fibroblast growth factor receptors | Q24301087 |
| | Phenotypic characterization of human colorectal cancer stem cells | Q24674126 |
| | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 |
| | Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma | Q27852856 |
| | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer | Q27853224 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice | Q27860831 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Identification of pancreatic cancer stem cells | Q28286997 |
| | Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes | Q29547633 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis | Q29614347 |
| | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 |
| | Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 |
| | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| | Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. | Q33609699 |
| | Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis | Q33926377 |
| | CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily | Q33964729 |
| | Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma | Q34385867 |
| | Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. | Q34394487 |
| | Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer | Q34414152 |
| | Second-line systemic treatment for advanced cholangiocarcinoma | Q34484299 |
| | Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer | Q34628085 |
| | Development of TGF-beta signalling inhibitors for cancer therapy | Q35968389 |
| | Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. | Q36116373 |
| | Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses | Q36586333 |
| | Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis | Q36980064 |
| | A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma | Q37325331 |
| | The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment | Q37399292 |
| P433 | issue | 3 | |
| P304 | page(s) | 524-533 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Promising therapeutics of gastrointestinal cancers in clinical trials | |
| P478 | volume | 8 | |